Corey J. Langer, MD, FACP
Professor of Medicine
University of Pennsylvania
Corey J. Langer, MD, FACP, is a Professor of Medicine in the Hematology/Oncology Division at the University of Pennsylvania in Philadelphia, where he serves as Director of Thoracic Oncology in the Abramson Cancer Center and co-leads its Translational Therapeutics Program. Dr. Langer received his Doctor of Medicine degree from Boston University and completed his internship and residency in medicine at the Graduate Hospital of the University of Pennsylvania in Philadelphia. Additional postgraduate training included a hematology/oncology fellowship at the Penn Presbyterian Medical Center and an oncology fellowship at American Oncologic Hospital, Fox Chase Cancer Center, in Philadelphia.
Dr. Langer is a fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the International Association for the Study of Lung Cancer (IASLC). He serves as Vice-Chairman of the Radiation Therapy Oncology Group (RTOG) and chairman of its Medical Oncology Subcommittee and maintains a leadership role as RTOG transitions into the NRG Cooperative Group. He also serves on the core thoracic and head and neck committees of both the Eastern Cooperative Oncology Group and RTOG. He serves on the Ethics Committee of the IASLC, and is a member of the Data Safety Monitoring Board of the Southwest Oncology Group.
Dr. Langer has contributed numerous articles and abstracts to the medical literature. His work on head and neck squamous cell cancer, non–small cell lung cancer, small cell carcinoma of the lung, and malignant mesothelioma has appeared in The New England Journal of Medicine, Seminars in Oncology, Clinical Cancer Research, the Journal of Clinical Oncology, the Journal of Thoracic Oncology, Clinical Lung Cancer, Cancer, Lung Cancer, Cancer Investigation, and the European Journal of Cancer. His work has also been presented at the national meetings of ASCO, AACR, the American Society of Hematology, and the IASLC. He has served three separate terms as a member of the editorial board of the Journal of Clinical Oncology and is currently on the editorial boards of Clinical Lung Cancer and Clinical Advances in Hematology and Oncology.
Corey J. Langer, MD, FACP, reported a financial interest/relationship or affiliation in the form of: grant/research support, Bristol-Myers Squibb Company, Pfizer, Inc., Eli Lilly and Company, Genentech, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma US, Inc.), Merck & Co., Inc., GlaxoSmithKline plc., and Nektar Therapeutics; scientific advisor, Bristol-Myers Squibb Company, ImClone LLC, sanofi US, Pfizer, Inc., Eli Lilly and Company, Amgen, Inc., AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Genentech, Inc., Bayer/Onyx, Abraxis BioScience, LLC, Abbott Laboratories, Morphotek, Inc., Biodesix, Inc., Clarient, Caris Life Sciences, Inc., Vertex Pharmaceuticals, Synta Pharmaceuticals Corp., Celgene Corporation, and Boehringer Ingelheim; speaker’s bureau, Eli Lilly and Company, Genentech, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma US, Inc.), and ImClone LLC - BMS; and data safety monitoring committee, Eli Lilly and Company, Amgen, Inc., Synta Pharmaceuticals Corp., and Agennix.
Maureen F. Zakowski, MD
Former Head of Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, New York
Maureen F. Zakowski, MD, is the leader of the Memorial Sloan Kettering Cancer Center (MSKCC) thoracic pathology team. Dr. Zakowski attended St. Louis University in Missouri and then pursued postgraduate studies at the City College of New York in Manhattan. Her work there led her to study basic medical sciences at the University of Brussels in Belgium, followed by medical studies at Ross University School of Medicine in the Commonwealth of Dominica, West Indies, where she was awarded a Doctor of Medicine degree.
As her training continued, Dr. Zakowski served as resident in pathology (combined anatomic and clinical pathology) at Hartford Hospital in Connecticut, where she later became the chief resident in anatomic pathology. She is experienced in all aspects of surgical pathology and cytopathology, and has been instrumental in identifying specific mutation profiles in lung cancers of different histologies. Dr. Zakowski is a member of the institutional Disease Management Team in Lung Cancer and has been central in the establishment of the Lung Cancer Mutation Analysis Program that provides reflexive mutation testing on all lung tumors at MSKCC. She provides expert diagnosis for lung cancer specimens and supervises the fresh tissue collection with the rebiopsy protocols that provide tissues banked by the molecular profiling and pathology core for different projects in collaboration with the MSKCC tumor procurement service. In reviewing histologic and cytologic material, Dr. Zakowski assesses adequacy of sampling, viability, and tumor response to various therapeutic agents, and interprets immunohistochemical results for validation studies on tissue sections, cytology preparations, and tissue microarrays.
Maureen F. Zakowski, MD, has no conflicts of interest to report.
Barbara J. Gitlitz, MD
Associate Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California
Barbara J. Gitlitz, MD, is an Associate Professor of Clinical Medicine at Keck School of Medicine at the University of Southern California (USC) in Los Angeles, where she spearheads the USC oncology effort in lung cancer and head and neck cancer. Much of her early clinical-translational work involved cancer immunotherapy, including one of the first trials of a dendritic cell vaccine for patients with kidney cancer. Dr. Gitlitz is board-certified in internal medicine and medical oncology. She received her Doctor of Medicine degree from the State University of New York at Stony Brook. She completed an internship in Medicine at the University of California in Los Angeles (UCLA), a residency in Internal Medicine at Cedars-Sinai Medical Center in Los Angeles, and fellowships in hematology/oncology and translational investigation at UCLA.
Dr. Gitlitz has authored or coauthored book chapters and hundreds of peer-reviewed scientific articles. She has been an invited lecturer at national and international conferences and has presented on topics related to lung cancer and head and neck cancer. Dr. Gitlitz received research grants from the American Cancer Society, the National Institutes of Health, and STOP CANCER. She is currently a member of the Stand Up to Cancer Epigenetics Dream Team, focusing on novel trials to treat lung cancer with immunotherapy and therapy to awaken important genes that are “turned off” by growing lung cancers. She is the principal investigator on a prospective study to characterize the somatic and germline genomics of lung cancer occurring in patients younger than age 40. Dr. Gitlitz has a passion for working with scientists seeking ways to personalize therapy and offer novel drugs and clinical trials to treat her patients. She believes that each person’s lung cancer may have unique molecular/genomic features to help guide the best treatment plan.
Barbara J. Gitlitz, MD, reported a financial interest/relationship or affiliation in the form of: speaker’s bureau, Genentech, Inc.; Lilly USA; and Pfizer, Inc.
David H. Harpole, Jr., MD
Professor of Surgery
Associate Professor of Pathology
Division of Thoracic Surgery
Department of Surgery
Duke University Medical Center
Durham, North Carolina
David H. Harpole, Jr. is a Professor of Surgery in the Division of Thoracic Surgery and an Associate Professor of Pathology in the Department of Pathology at the Duke University Medical Center in Durham, North Carolina, where he also directs the Lung Cancer Biorepository. Dr. Harpole has served in the Department of Surgery and Division of Thoracic Surgery since 1996. During his tenure there, he served as Vice Chairman for Faculty Affairs, Vice Chief of Surgical Sciences, and is currently Vice Chairman for Research in the Department of Surgery. He also served as the Surgical Coordinator for Duke University Medical Center, Cancer and Leukemia Group B; Chairman, Society of Thoracic Surgeons, General Thoracic Surgery Database; Chairman, Thoracic Surgery subcommittee, CALGB; Vice Chairman, American College of Surgeons Oncology Group; Co-chairman of the Thoracic Tumor Committee of the National Cancer Database; and Director of the American Board of Thoracic Surgery.
Dr. Harpole has contributed numerous articles and abstracts to the medical literature. His work on non–small cell lung cancer and esophageal carcinoma has appeared in the Journal of Thoracic & Cardiovascular Surgery, Clinical Cancer Research, the Journal of Clinical Oncology, the Journal of Thoracic Oncology, Cancer, and Lung Cancer. His work has also been presented at national meetings of the American Society of Clinical Oncology, the American Association for Cancer Research, the Society of Thoracic Surgeons, and the International Association for the Study of Lung Cancer. Dr. Harpole received his Doctor of Medicine degree from the University of Virginia in Charlottesville and completed his internship, residency, and fellowship in general surgery and thoracic surgery at Duke University Medical Center.
David H. Harpole Jr., MD, has no conflicts of interest to report.
Leora Horn, MD, MSc, FRCPC
Vanderbilt University School of Medicine
Vanderbilt-Ingram Cancer Center
Leora Horn, MD, MSc, FRCPC, is an Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University. She is also the Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC). Dr. Horn’s clinical practice focuses primarily on the care of patients with lung cancer. Her research interests include experimental therapeutics and medical education. She recently received a VICC Impact award for her research contributions.
Dr. Horn is a principal investigator on several lung cancer clinical trials and educational projects. She has published more than 40 papers and book chapters including original papers and reviews in the Journal of Clinical Oncology and The New England Journal of Medicine. She is an active member in the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada. Dr. Horn is currently completing a master’s degree program in Health Professional Education through the University of Illinois at Chicago and has a cross appointment to the Office of Teaching and Learning in Medicine where she is the Assistant Director of the Educator Development Program (EDP) at Vanderbilt. She received her Honors Bachelor of Science and Master of Science degrees in Pharmacology from the University of Toronto, where she attended medical school and trained in internal medicine and medical oncology.
Leora Horn, MD, MSc, reported a financial interest/relationship or affiliation in the form of: consulting fee, Bristol-Myers Squibb Company, Clovis Oncology, and Helix BioPharma; contracted research, Astellas Pharma US, Inc.; and honoraria, Boehringer Ingelheim.
M. Patricia Rivera, MD
Professor of Medicine
Division of Pulmonary Diseases & Critical Care Medicine
Department of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Dr. Rivera is a Professor of Medicine in the Pulmonary Division, Department of Medicine at The University of North Carolina at Chapel Hill (UNC). She joined the UNC faculty in 1995 and is a co-director of the Multidisciplinary Thoracic Oncology Program, which she helped to establish. She is also the Director of the Pulmonary Function and Bronchoscopy Laboratories at UNC.
Dr. Rivera received her Doctor of Medicine degree from the State University of New York at Stony Brook. She performed her internship and residency in internal medicine at North Shore University Hospital in Manhasset, New York. She completed a Pulmonary Medicine/Critical Care Fellowship at Memorial Sloan Kettering Cancer Center in New York, New York. She is a fellow of the American College of Chest Physicians (ACCP). She served as chairperson and co-chairperson of the Thoracic Oncology Network of the ACCP and has been an editor and writer for the ACCP Lung Cancer Guidelines. She is also a member of the American Thoracic Society and is an active committee member of the Thoracic Oncology Assembly.
Dr. Rivera’s research interest focuses on lung cancer and early detection of premalignant lesions using fluorescence bronchoscopy. She is currently co-director of the Lung Cancer Screening Clinic at UNC. She has received several honors and awards, including the Governor’s award from North Carolina for the ACCP, University of North Carolina School of Medicine 1998 Whitehead Lecturer, University of North Carolina 2005 White Coat Ceremony Keynote Speaker, and Humanitarian in Medicine Award Nominee in 2004.
M. Patricia Rivera, MD, has no conflicts of interest to report.
Heather Wakelee, MD
Department of Medicine, Division of Oncology
Stanford Clinical Cancer Center
Dr. Wakelee is Assistant Professor of Medicine at Stanford University in the Division of Oncology in Palo Alto, California, where she is the co-leader of the lung cancer disease management group. She focuses on clinical research in patients with lung cancer and has a particular interest in anti-angiogenesis agents. Dr. Wakelee is the principal investigator of the ongoing International Lung Cancer Intergroup trial E1505 that is investigating the potential role of bevacizumab in addition to adjuvant chemotherapy for resected early stage, non–small cell lung cancer. She is also conducting a trial with a related compound known as aflibercept (VEGF-TRAP) and a trial with the vascular disrupting agent ASA404.
Dr. Wakelee is an active member of the Eastern Cooperative Oncology Group and is the principal investigator of a large adjuvant trial for patients with completely resected lung cancer who are randomized to chemotherapy or chemotherapy plus bevacizumab. She is also involved in several collaborative efforts with her colleagues in thoracic surgery and radiation oncology (a multidisciplinary trial for stage III non–small cell lung cancer and cyberknife protocols for patients with early stage disease who are not eligible for surgery), as well as in pulmonary medicine (analysis of blood samples for circulating lung tumor cells and other basic science projects).
Dr. Wakelee attended Princeton University, Princeton, New Jersey, as an undergraduate with a major in molecular biology. She then attended medical school at Johns Hopkins University, Baltimore, Maryland, before returning to her native California for an internal medicine residency and fellowship training in medical oncology at Stanford University.
Heather Wakelee, MD, reported a financial interest/relationship or affiliation in the form of: speaker’s bureau, Peregrine Pharmaceuticals, Inc.; contracted research, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb / Exelixis Inc., Celgene Corporation, Clovis Oncology, Genentech- A member of the Roche Group, Lilly USA, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Xcovery.
Rex Chin-Wei Yung, MD, FCCP
Director of Bronchology and Pulmonary Oncology (Retired, 2014)
Voluntary Clinical Faculty
Johns Hopkins University
Baltimore Medical Center
Dr. Rex Chin-Wei Yung was Director of Bronchology and Pulmonary Oncology in the Department of Medicine, the Division of Pulmonary and Critical Care Medicine at Johns Hopkins University (JHU) from 2000 until his retirement in 2014. He continues to work with JHU as a voluntary faculty member and assists with preclinical research at JHU specifically with image-guided diagnosis and interventions for lung cancer. Dr. Yung was an undergraduate at Harvard University, Cambridge, Massachusetts; received his medical degree from the University of California in Los Angeles; and underwent subspecialty training in pulmonary and critical care medicine at the University of California in San Francisco.
Dr. Yung has co-authored and lectured on the importance of developing multidisciplinary collaborations and standardizing such a team approach for the evaluation and management of lung cancers across the spectrum of cancer stages, cell types, and care cycle in his leadership roles locally at the institutional level; nationally at the American College of Chest Physician governors association and guidelines committees, American Lung Association subcommittee for early lung cancer detection; and internationally with the International Association for the Study of Lung Cancer Early Detection and Prevention working group and the World Association of Bronchoscopy and Interventional Pulmonology Executive Board.
Rex Chin-Wei Yung, MD, FCCP, reported a financial interest/relationship or affiliation in the form of: consulting fee, FreshMedical; and contracted research, Philips North America.